Business
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
Interim Results for the period ended 30 June 2025 LONDON, UK / ACCESS Newswire / September 30, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose Shares ...
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"Interim Results for the period ended 30 June 2025","length":49,"tagName":"p"},{"type":"text","content":"LONDON, UK / ACCESS Newswire / September 30, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose Shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month period ended 30 June 2025.","length":365,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":463,"height":142,"url":"https://media.zenfs.com/en/accesswire.ca/230be9a96599405d743be4079454c576"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ecWci4B3P8uzCZtl1EsyjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxNjtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/230be9a96599405d743be4079454c576","width":463,"height":142}}},{"type":"text","content":"All financial amounts are stated in GBP British pounds unless otherwise indicated.","length":82,"tagName":"p"},{"type":"text","content":"Key Highlights","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First-in-human treatment with HG-CT-1 successfully administered.","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Three patients treated to date in Phase I trial; all passed initial safety evaluations with encouraging early signs of efficacy.","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA accepted Annual IND report for HG-CT-1.","length":43,"tagName":"p"}]},{"val":[{"type":"text","content":"Pediatric expansion of the Phase I trial cleared by FDA following protocol amendment.","length":85,"tagName":"p"}]},{"val":[{"type":"text","content":"£2.24 million raised in H1 2025 to support ongoing clinical development.","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":392,"olType":false},{"type":"text","content":"Fuller details of these developments are contained in the Interim Management Report below.","length":90,"tagName":"p"},{"type":"text","content":"Interim Management Report","length":25,"tagName":"p"},{"type":"text","content":"We are pleased to present the Hemogenyx Pharmaceuticals half year report for the period ended 30 June 2025. The first half...